Despite promising findings from preclinical and observational clinical studies, challenges persist
Unlike full-length growth hormone, which can cause edema (fluid retention), joint pain, carpal tunnel syndrome, glucose elevation, and increased IGF-1, AOD-9604 demonstrates none of these effects in clinical trials

KEY TAKEAWAYS: Target +0.15% protein gains through genetic selection current Federal Milk Marketing Order pricing heavily favors protein over fat, with real farms seeing $3,000+ monthly increases Prioritize A2A2 beta-casein and favorable kappa-casein genetics these variants are commanding 10-15% premiums as processors chase functional food contracts in 2025 Partner with processors now about protein premium contracts 57% of GLP-1 users maintain dairy consumption while needing muscle-preserving nutrition, creating immediate market opportunities Consider the $150,000-$200,000 investment for functional food processing payback periods of 18-24 months make this compelling for mid-scale operations ready to capture value-added markets Monitor healthcare-driven consumer trends closely the pharmacy aisle now directly influences dairy demand, and early movers will define the next era of dairy profitability Danones new cultured dairy drink, explicitly designed for the booming GLP-1 user market, isnt just another product launchits a strategic shot across the bow that signals a fundamental shift in the valuation of dairy protein

Precise Dosing : IV therapy allows for exact dosing based on your individual needs and liver function status
Patients are estimated to lose 15%-20% of their body weight, with a weight-loss money-back guarantee
Next-generation GLP-1 medications like retatrutide and mazdutide build on the foundation semaglutide established